Xtant Medical Holdings Inc (XTNT)

$0.78

+0.03

(+3.52%)

Market is closed - opens 7 PM, 23 May 2024

Insights on Xtant Medical Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 14.46M → 28.10M (in $), with an average increase of 10.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 9.23M → -4.30M (in $), with an average decrease of 73.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.3% return, outperforming this stock by 22.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.0% return, outperforming this stock by 127.3%

Performance

  • $0.74
    $0.80
    $0.78
    downward going graph

    5.0%

    Downside

    Day's Volatility :7.94%

    Upside

    3.09%

    downward going graph
  • $0.60
    $1.45
    $0.78
    downward going graph

    22.88%

    Downside

    52 Weeks Volatility :58.52%

    Upside

    46.21%

    downward going graph

Returns

PeriodXtant Medical Holdings IncIndex (Russel 2000)
3 Months
-25.0%
0.0%
6 Months
-39.06%
0.0%
1 Year
23.73%
0.0%
3 Years
-45.45%
-20.1%

Highlights

Market Capitalization
98.1M
Book Value
$0.39
Earnings Per Share (EPS)
0.01
PE Ratio
75.35
PEG Ratio
-0.03
Wall Street Target Price
2.35
Profit Margin
0.72%
Operating Margin TTM
-13.54%
Return On Assets TTM
-8.31%
Return On Equity TTM
1.54%
Revenue TTM
91.3M
Revenue Per Share TTM
0.77
Quarterly Revenue Growth YOY
84.1%
Gross Profit TTM
32.1M
EBITDA
-7.0M
Diluted Eps TTM
0.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.08
EPS Estimate Next Year
-0.01
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Xtant Medical Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 201.28%

Current $0.78
Target $2.35

Company Financials

FY18Y/Y Change
Revenue
72.2M
↓ 12.6%
Net Income
-70.1M
↑ 33.75%
Net Profit Margin
-97.09%
↓ 33.65%
FY19Y/Y Change
Revenue
64.7M
↓ 10.42%
Net Income
-8.2M
↓ 88.27%
Net Profit Margin
-12.71%
↑ 84.38%
FY20Y/Y Change
Revenue
53.3M
↓ 17.54%
Net Income
-7.0M
↓ 14.57%
Net Profit Margin
-13.17%
↓ 0.46%
FY21Y/Y Change
Revenue
55.3M
↑ 3.61%
Net Income
-5.8M
↓ 16.79%
Net Profit Margin
-10.57%
↑ 2.6%
FY22Y/Y Change
Revenue
58.0M
↑ 4.9%
Net Income
-8.5M
↑ 45.19%
Net Profit Margin
-14.64%
↓ 4.07%
FY23Y/Y Change
Revenue
91.3M
↑ 57.5%
Net Income
660.0K
↓ 107.78%
Net Profit Margin
0.72%
↑ 15.36%
Q4 FY22Q/Q Change
Revenue
15.3M
↑ 5.59%
Net Income
-2.2M
↓ 6.12%
Net Profit Margin
-14.47%
↑ 1.8%
Q1 FY23Q/Q Change
Revenue
17.9M
↑ 17.5%
Net Income
-2.1M
↓ 5.93%
Net Profit Margin
-11.58%
↑ 2.89%
Q2 FY23Q/Q Change
Revenue
20.2M
↑ 12.76%
Net Income
-2.2M
↑ 5.39%
Net Profit Margin
-10.82%
↑ 0.76%
Q3 FY23Q/Q Change
Revenue
25.0M
↑ 23.66%
Net Income
9.2M
↓ 521.51%
Net Profit Margin
36.9%
↑ 47.72%
Q4 FY23Q/Q Change
Revenue
28.1M
↑ 12.35%
Net Income
-4.3M
↓ 146.61%
Net Profit Margin
-15.31%
↓ 52.21%
Q1 FY24Q/Q Change
Revenue
28.1M
↑ 0.0%
Net Income
-4.3M
↑ 0.0%
Net Profit Margin
-15.31%
↑ 0.0%
FY18Y/Y Change
Total Assets
46.4M
↓ 56.08%
Total Liabilities
90.2M
↓ 45.14%
FY19Y/Y Change
Total Assets
43.2M
↓ 7.04%
Total Liabilities
87.4M
↓ 3.14%
FY20Y/Y Change
Total Assets
41.5M
↓ 3.91%
Total Liabilities
27.0M
↓ 69.15%
FY21Y/Y Change
Total Assets
54.7M
↑ 31.9%
Total Liabilities
23.8M
↓ 11.66%
FY22Y/Y Change
Total Assets
60.2M
↑ 10.12%
Total Liabilities
26.1M
↑ 9.45%
FY23Y/Y Change
Total Assets
92.6M
↑ 53.77%
Total Liabilities
41.3M
↑ 58.35%
Q4 FY22Q/Q Change
Total Assets
60.2M
↑ 7.46%
Total Liabilities
26.1M
↑ 11.95%
Q1 FY23Q/Q Change
Total Assets
63.3M
↑ 5.13%
Total Liabilities
30.6M
↑ 17.45%
Q2 FY23Q/Q Change
Total Assets
65.2M
↑ 3.0%
Total Liabilities
34.3M
↑ 11.94%
Q3 FY23Q/Q Change
Total Assets
92.0M
↑ 41.07%
Total Liabilities
37.3M
↑ 8.94%
Q4 FY23Q/Q Change
Total Assets
92.6M
↑ 0.66%
Total Liabilities
41.3M
↑ 10.56%
Q1 FY24Q/Q Change
Total Assets
92.6M
↑ 0.0%
Total Liabilities
41.3M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
1.2M
↓ 323.13%
Investing Cash Flow
-367.0K
↓ 77.18%
Financing Cash Flow
3.1M
↑ 27.46%
FY19Y/Y Change
Operating Cash Flow
-413.0K
↓ 134.08%
Investing Cash Flow
-544.0K
↑ 48.23%
Financing Cash Flow
-603.0K
↓ 119.48%
FY20Y/Y Change
Operating Cash Flow
-731.0K
↑ 77.0%
Investing Cash Flow
-1.3M
↑ 139.71%
Financing Cash Flow
-861.0K
↑ 42.79%
FY21Y/Y Change
Operating Cash Flow
439.0K
↓ 160.05%
Investing Cash Flow
-1.9M
↑ 44.94%
Financing Cash Flow
17.5M
↓ 2132.17%
FY22Y/Y Change
Operating Cash Flow
-5.3M
↓ 1316.63%
Investing Cash Flow
-1.6M
↓ 17.51%
Financing Cash Flow
9.0M
↓ 48.45%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.3M
↑ 10.85%
Investing Cash Flow
-422.0K
↓ 14.23%
Financing Cash Flow
5.6M
↑ 69.5%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.2M
↓ 1.88%
Investing Cash Flow
-17.4M
↑ 4028.2%
Financing Cash Flow
4.6M
↓ 18.61%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.5M
↑ 12.29%
Investing Cash Flow
-394.0K
↓ 97.74%
Financing Cash Flow
2.0M
↓ 57.26%

Technicals Summary

Sell

Neutral

Buy

Xtant Medical Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xtant Medical Holdings Inc
Xtant Medical Holdings Inc
-14.19%
-39.06%
23.73%
-45.45%
-77.06%
Stryker Corporation
Stryker Corporation
0.15%
14.23%
22.34%
30.44%
81.8%
Boston Scientific Corp.
Boston Scientific Corp.
9.25%
35.48%
46.35%
76.1%
99.44%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
2.8%
32.86%
6.46%
-5.49%
59.22%
Abbott Laboratories
Abbott Laboratories
-2.57%
1.9%
-0.87%
-10.63%
38.6%
Medtronic Plc
Medtronic Plc
5.5%
8.6%
-1.57%
-33.05%
-6.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xtant Medical Holdings Inc
Xtant Medical Holdings Inc
75.35
75.35
-0.03
-0.08
0.02
-0.08
NA
0.39
Stryker Corporation
Stryker Corporation
37.73
37.73
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.59
63.59
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.77
38.77
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.07
32.07
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.04
27.04
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xtant Medical Holdings Inc
Xtant Medical Holdings Inc
Buy
$98.1M
-77.06%
75.35
0.72%
Stryker Corporation
Stryker Corporation
Buy
$125.9B
81.8%
37.73
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.2B
99.44%
63.59
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.4B
59.22%
38.77
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.1B
38.6%
32.07
13.96%
Medtronic Plc
Medtronic Plc
Buy
$113.1B
-6.42%
27.04
13.0%

Company Information

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Organization
Xtant Medical Holdings Inc
Employees
207
CEO
Mr. Sean E. Browne
Industry
Health Technology

FAQs